Jiangsu Hengrui Pharmaceuticals (600276.SH): SHR-1819 injection receives notification of approval for drug clinical trials.

10/01/2025

GMT Eight

Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that its subsidiary Guangdong Jiangsu Hengrui Pharmaceuticals Co., Ltd. has received the approval notification for clinical trial of SHR-1819 injection from the National Medical Products Administration (NMPA) and will soon begin clinical trials. It is reported that SHR-1819 injection is a recombinant humanized monoclonal antibody targeting human IL-4R independently developed by the company, which can simultaneously block the signaling of IL-4 and IL-13 and is intended for the treatment of type 2 inflammation-related diseases.

OOIL(00316): Orient Overseas (International) Ltd. reported total fourth quarter revenue of 2.514 billion US dollars, an increase of 55.0% year-on-year.

Yizumi Holdings (300415.SZ) announces that it is expecting a yearly net profit of 585 million to 646 million yuan, a year-on-year increase of 22.53% to 35.45%.

Contact: contact@gmteight.com

Jiangsu Hengrui Pharmaceuticals (600276.SH): SHR-1819 injection receives notification of approval for drug clinical trials.

RECOMMEND

Jinyuan EP Co., Ltd. (000546.SZ): Zhao Hui and Fang Guangquan received a warning letter from Jilin Securities Regulatory Bureau.

ELIFE HLDGS(00223): Application for injunction hearing postponement

Goldman Sachs monitors the crude oil market: Oil prices break through the 100-day moving average, triggering algorithmic trading. Demand for oil will expand due to the cold winter.